Design-Development-and-5

Design, Development And Characterization Of Chewable Orlistat Disintegrating Tablets

$ 4.09

by Bhavani Boddeda(Author),Swathi Putta(Author),Ch SS Prasad(Author)

ISBN Number : 978 – 1- 73040 – 121 – 3

Compare
SKU: SBP_1632 Category:

Description

Bhavani Boddeda
M.Pharm., Ph.D. Associate Professor,
Vignan Institute of Pharmaceutical Technology, Visakhapatnam

Swathi Putta
AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam

Ch SS Prasad
AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam

Orlistat is a novel, non-systemically acting anti obesity agent, it has biological half life of
1-2hr. Frequent administration of this agent is necessary due to its short biological half
life. This selectively inhibits the absorption of approximately 30% of fatty components
from the diet. Orlistat is prone to both hydrolysis and thermolysis, when stored in
conditions above its melting point (42–44 °C), Orlistat is highly lipophilic and practically
insoluble in water and is sticky nature of the powder it very difficult to formulate tablet.
Different research scalar shows poor stability and poor Patient compliance. Hence to
deigned Orlistat chewable tablets to overcome all the above disadvantages. The Orlistat
chewable tablet is expected to prove following benefits.
1. To improve physical and chemical stability
2. To improve therapeutic action
3. To treat obesity for adolescents
4. To release the drug immediately at local site for immediate therapeutic action.
5. To minimize toxic effects
6. To reduce dose
7. To enhance solubility of drug
8. To maintain long term stability of dosage form
9. To reduce cost by using simple technique.
10. To treat anti obesity and type-2 diabetes, and hypertension and arthritis.
11. To improve patient compliance.
The present study polymers such as fatty acids are selected for to formulate stable
chewable tablet by using melt granulation technique. The major objective of the present
investigations to formulate and evaluate chewable Orlistat tablets selected as fatty acids
by using melt granulation technique.
The major objective of the investigations as follows
1. Identification of API.
2. Stability studies of Orlistat.
3. Drug and polymer interaction studies (IR spectrum studies).
4. To conduct the Pre-formulation studies.
5. Analytical method development.
6. To optimize the selection of polymers.
7. To optimize concentration of polymer.
8. To enhance the solubility of the drug by using different techniques.
9. To determine evaluation parameters.
10. To evaluate the prepared tablets as per the pharmacopeial standards.
11. To determine the rate of dissolution.
12. To compare formulated Orlistat tablet with marketed product (Xenical).
13. To conduct stability studies for dosage form.
14. To study micro metric parameters before to compression.1,4,8.